|This Slide: #11 of 100|
Slide #11. Alliqua — Choice Therapeutics
Alliqua, Inc. (Nasdaq:ALQA) ("Alliqua" or the "Company"), a provider of advanced wound care products, has acquired Choice Therapeutics, Inc. ("Choice Therapeutics"), a privately held wound care company with proprietary technologies and products, for approximately $4 million in stock and cash. The merger agreement, which became effective May 5, 2014, provides for additional contingent payments of up to $5 million in stock or cash, under certain circumstances, if stated revenue thresholds are reached over the next three years ending April 30, 2017. The acquisition is expected to be accretive to Alliqua's earnings during the next 12 months.
Adynxx is a technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. Co.'s subsidiary, Celleration, Inc. developed the MIST® Ultrasound Healing Therapy (MIST Therapy) therapeutic ultrasound platform for the treatment of acute and chronic wounds. MIST Therapy is a noncontact, low-frequency ultrasound delivered through a saline mist to the wound bed. Co. has a license in intellectual property related to certain placental based products for wound care and wound management, including those made from extracellular matrix derived from the human placenta, and Biovance® Amniotic Membrane Allograft.
Open the ALQA Page at The Online Investor »
Free ALQA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite